The impact of human leukocyte antigen (HLA) allele mismatch on transplant outcomes in haploidentical stem cell transplantation (haplo-SCT) has not been established. We retrospectively studied 595 patients with hematologic malignancy who received haplo-SCT. The impact of multiple HLA allele mismatches (HLA-A, -B, -C, -DRB1, and -DQB1) and each HLA allele mismatch on transplant outcomes was analyzed. Greater number of HLA allele disparity does not appear worsen outcome. As for each HLA locus, HLA-A mismatch correlated with decreased rate of platelet engraftment (HR 0.740, P = .003); HLA-B mismatch independently correlated with decreased relapse rate (HR 0.494, P = .032) and improved disease-free survival and overall survival (HR 0.514, P = .003; HR 0.494, P = .002, respectively); HLA-C mismatch appeared to be protective for transplant-related mortality (TRM) (HR 0.567, P = .039); HLA-DRB1 mismatch was associated with increased cumulative incidence of grade II-IV acute graft-vs.-host disease (GVHD) (HR 1.942, P = .002). No associations of any HLA mismatch with delayed neutrophil engraftment or increased cumulative incidence of chronic GVHD were observed. Our data indicated that high degree of HLA allele mismatches did not adversely affect transplant outcomes in haplo-SCT and each HLA allele mismatch had different effect.
Introduction
Haploidentical stem cell transplantation (haplo-SCT) is an attractive option for patients without matching human leukocyte antigen (HLA) related or unrelated donors. Although donor HLA matching is associated with better outcomes after unrelated hematopoietic SCT [1] [2] [3] [4] , the impact of HLA disparity on transplant outcomes under haplo-SCT still remains incompletely understood.
Our previous study found that the greater number of HLA antigen mismatch at HLA-A, -B, and -DRB1 did not correlate with any transplant outcomes after haplo-SCT with granulocyte colony-stimulating factor (G-CSF) and antithymocyte globulin (ATG) based protocol [5] [6] [7] [8] . Similar results were also observed in other transplant centers [9] [10] [11] [12] . However, Kasamon et al. found that having more allele mismatches at HLA-A, -B, -C, and -DRB1 appeared to be protective on multivariate analysis of disease-free survival (DFS) after nonmyeloablative haplo-SCT with high-dose post-transplantation cyclophosphamide (PT/CY) [13] .
Meanwhile, the relative importance of each HLA locus in haplo-SCT remains largely unknown, and the results from a small number of previous studies vary [14] [15] [16] [17] . One study from our group demonstrated that HLA-B antigen mismatch was an independent risk factor for acute GVHD and transplant-related mortality (TRM) after myeloablative haplo-SCT with ATG [18] . Another study from Kasamon et al. reported that HLA-DRB1 antigen mismatch appeared to be protective after nonmyeloablative haplo-SCT with high-dose PT/CY [13] . Which HLA locus is more important in haplo-SCT needs to be further studied.
Therefore, we retrospectively identified the genotype of HLA-A, -B, -C, -DRB1, and -DQB1 in 595 donor-recipient pairs under haplo-SCT and analyzed the impact of HLA allele disparity on transplant outcomes.
Materials and methods

Patients
A total of 595 patients with leukemia or myelodysplastic syndrome (MDS) receiving haplo-SCT between January 2010 and March 2014 were considered. Patients who received a second SCT were excluded. The characteristics of patients and donors were listed in Table 1 . The median follow-up time was 701 days (range, 190-1434 days).
Informed consent was obtained from patients and donors in accordance with the Declaration of Helsinki, and the approval of the study was obtained from the Institutional Review Board of Peking University.
Transplant procedure
Transplant procedures including stem cell collection, conditioning regimen, GVHD prophylaxis, and supportive care were described in our previous reports [6, 8, 19] . All of the recipients received mixture allografts of G-CSF-mobilized bone marrow and peripheral blood stem cell harvests.
Notably, between December 2010 and May 2012, leukemia subjects with standard stage (defined below) were randomized to receive ATG 2.5 mg/kg per day or 1.5 mg/kg per day (study registered at www.chictr.org #ChiCTR-TRC-11001761) [20] . Overall, 79 of 595 subjects received an ATG total dose of 6 mg/kg, and the remaining 516 subjects received 10 mg/kg.
GVHD prophylaxis regimen consisted of cyclosporine A, mycophenolate mofetil, and short-term methotrexate. A total of 52 patients who were considered high risk (CD4: CD8≥1.16) of acute GVHD received low-dose corticosteroid prophylaxis [19] .
Donor lymphocyte infusions (DLIs) were administered as described previously [21, 22] . Patients with minimal residual disease (MRD)-positive but could not receive DLI after haplo-SCT received preemptive interferon-α (IFN-α) treatment alternatively. In total, 76 patients received preemptive DLI or IFN-α.
HLA typing
HLA-A, -B, and -DRB1 were typed by the polymerase chain reaction-sequence specific oligonucleotide (PCR-SSO) probes followed the recommendations of the manufacturer (LABRType, One lambda Inc., Canoga Park, CA) before transplantation. HLA-C and HLA-DQB1 were typed by the PCR-sequencing based typing (SeCoreR, Invitrogen, Brown Deer, WI, USA) using available DNA. In the analysis of acute and chronic GVHD, an HLA mismatch among the donor-recipient pair was defined when the recipient's alleles were not shared by the donor (GVH vector), and engraftment failure when the donor's alleles were not shared by the recipient (HVG vector). In the analysis of relapse, death, and survival, the mismatch was defined as that of either GVHD vector or HVG vector.
Definitions
Subjects with acute leukemia in the first complete remission, chronic myeloid leukemia in the first chronic phase, and MDS with <20% bone marrow blasts were categorized as standard stage. Other subjects were classified as high risk [2, 8] . Neutrophil engraftment defined as the absolute neutrophil count >0.5 × 10 9 /L for 3 consecutive days, and platelet engraftment defined as the platelet count >20 × 10 9 / L for 7 consecutive days without platelet transfusion.
GVHD was scored as acute or chronic based on published criteria [23] . Transplant-related mortality (TRM) was defined as death from any cause other than recurrent malignancy. Relapse was defined as hematologic recurrence of the primary disease. 
Statistical analysis
Comparisons between the subset of cases used the Mann-Whitney U test for continuous variables and the χ 2 test for categorical variables. Probabilities for overall survival and DFS were calculated using the Kaplan-Meier method. Death was considered a competing risk for all of the end points except overall survival and DFS. Relapse was also considered a competing event for TRM. Univariate comparisons of survival curves were made using the logrank test; the Gray test was used for univariate comparisons of cumulative incidence functions. Multivariate Cox proportional hazards models were built to adjust for clinical factors associated with outcomes. Clinical covariates considered in the multivariate models were donor age, recipient age, donor-recipient sex match, donor-recipient blood type match, disease type, and disease stage. Cytomegalovirus (CMV) serological state was not considered as a covariate, because only 1% of subjects were low risk for CMV reactivity [8] . Statistical analyses were performed using the SPSS (SPSS Inc/IBM, Armonk, NY) and R (R Development Core Team, Vienna, Austria) software. A P value of <0.05 was considered statistically significant.
Results
Effect of HLA allele disparity on transplant outcomes
To analysis the effect of greater number of HLA allele disparity (HLA-A, -B, -C, -DRB1, and -DQB1) on transplant outcomes, we divided donor-recipient pairs into 3 groups according to the number of mismatched HLA alleles: 0-3 HLA allele mismatches, 4 HLA allele mismatches, and 5 HLA allele mismatches. Consistent with our previous reports [5, 8, 18] , overall degree of HLA allele disparity had no association with transplant outcomes, including relapse, acute, and chronic GVHD, TRM, DFS, and OS (Fig. 1) . No significant differences in patients or donor characteristics were found between three groups.
Effect of each HLA allele mismatch on transplant outcomes
To see the impact of each HLA allele mismatch on transplant outcomes, we examined the association between specific HLA locus allelic mismatch and clinical outcome including the engraftment, relapse, acute, and chronic GVHD, TRM, DFS, and OS.
Engraftment
The neutrophil engraftment occurred at a median of 12 days (range, 8-45 days). There was no significant association between any HLA locus allelic mismatch and neutrophil engraftment. The platelet engraftment occurred at a median of 16 days (range, 5-196 days). The 100-day cumulative incidence of platelet engraftment was significantly higher in HLA-A matched group compared with HLA-A mismatched group by the univariate analysis (93.2 ± 8.8% vs 84.0 ± 5.2%, P = .003) (Fig. 2a) . HR of HLA allele mismatch compared with HLA allele match for platelet engraftment was highly significant in the HLA-A (0.740, P = .003), but was not significant in the HLA-B, -C, -DRB1, or -DQB1 by multivariate analysis (Table 2; Table S1 ).
Relapse
The 3-year cumulative incidence of relapse was 17.3 ± 0.2% for the entire population. In univariate analysis, the cumulative incidence of relapse was lower in HLA-B mismatched group compared with HLA-B matched group (12.7 ± 0.03% vs 19.7 ± 0.3%, P = .029) (Fig. 2b) . We did not observe significant associations between any other HLA mismatch and relapse. In multivariate analysis, HR of HLA allele mismatch compared with HLA allele match for relapse was highly significant in HLA-B (0.494, P = .032), but not significant in HLA-A, -C, -DRB1, or -DQB1 (Table 2; Table S1 ).
In order to exclude the influence of DLI and IFN-α on relapse, we further analyzed the effect of HLA-B mismatch on relapse in 519 patients who did not receive preemptive DLI or IFN-α. Similarly, HLA-B allele mismatch was still significantly associated with lower relapse rate (HR 0.399, P = .018).
Acute and chronic GVHD
The cumulative incidence of grade II-IV and grade III-IV acute GVHD for the entire population was 33.1 ± 1.9% and 7.5 ± 1.1%, respectively. The cumulative incidence of grade II-IV acute GVHD was significantly higher in HLA-DRB1 mismatched group compared with HLA-DRB1 matched group (34.8 ± 2.1% vs 18.7 ± 4.5%, P = .004) (Fig. 2c) . Consistent with the univariate result, HLA-DRB1 mismatch was associated with higher cumulative incidence of grade II-IV acute GVHD in the multivariate model (HR 1.942, P = .002) ( Table 2 ; Table S2 ). HLA-DRB1 mismatch had no significant association with higher cumulative incidence of grade III-IV acute GVHD compared with HLA-DRB1 match (7.3 ± 1.2% vs 6.0 ± 2.2%, P = .799).
The cumulative incidence of chronic GVHD was 31.0 ± 2.1% and there was no association between any HLA mismatch and chronic GVHD (Table S2) .
The low-dose ATG and low-dose corticosteroid prophylaxis have been reported influencing the incidence of acute GVHD [19, 20] . Therefore, we excluded 79 patients who received an ATG total dose of 6 mg/kg in the conditioning treatment, and 52 patients who received low-dose corticosteroid prophylaxis. Unexpectedly, HLA-DRB1 mismatch was not significantly associated with higher cumulative incidence of grade II-IV acute GVHD in the remaining 464 patients (HR 1.690, P = .074).
TRM
The 3-year TRM was 16.1 ± 1.6% for the entire population. HLA-C mismatch was associated with significantly decreased TRM compared with HLA-C match (14.8 ± 1.7% vs 23.8 ± 4.9%, P = .043) (Fig. 2d) . We did not observe significant associations of any other HLA mismatch with TRM. In the multivariate analysis, HR of HLA mismatch compared with HLA match for TRM was highly significant in HLA-C (HR 0.567, P = .039), but was not significant in HLA-A, -B, -DRB1, or -DQB1 (Table 2; Table S3 ).
DFS
The 3-year DFS was 71.7 ± 2.2% for the entire population. The 3-year DFS was significantly higher in HLA-B mismatched group compared with HLA-B matched group (73.2 ± 2.3% vs 57.5 ± 6.7%, P = .002) (Fig. 2e) . We did not observe significant associations of any other HLA mismatch with DFS. In the multivariate analysis, HR of HLA mismatch compared with HLA match for DFS was highly significant in HLA-B (HR 0.514, P = .003), but was not significant in HLA-A, -C, -DRB1, or -DQB1 (Table 2;  Table S3 ).
OS
The 3-year OS for the entire population was 74.2 ± 2.2%. The 3-year OS was significantly higher in HLA-B mismatched group compared with HLA-B matched group (77.2 ± 2.0% vs 57.5 ± 7.0%, P = .001) (Fig. 2f) . We did not observe significant associations of any other HLA mismatch with OS, although there was a trend of higher OS in HLA-C mismatch group compared with HLA-C matched group (76.6 ± 2.1% vs 66.7 ± 5.6%, P = .076). In the multivariate analysis, HR of HLA mismatch compared with HLA match for OS was highly significant in HLA-B (HR 0.494, P = .002), but was not significant in HLA-A, -C, -DRB1, or -DQB1 (Table 2; Table S3 ).
Other clinical factors and transplant outcomes
Compared to patients with standard stage disease at transplantation, patients with high risk stage showed worse outcomes in relapse risk (HR 3.130, P < .001), TRM (HR 1.995, P = .003), DFS (HR 2.386, P < .001), and OS (HR 2.225, P < .001) in multivariate model (Table 2) . Meanwhile, patients with high risk stage disease had a higher rate of platelet engraftment compared with the standard stage (HR 0.760, P = .011) ( Table 2) .
Discussion
This study confirms and updates previous knowledge of the impact of HLA allele mismatch in haplo-SCT. The most important findings of this study included: (i) greater number of HLA disparity did not appear worsen outcome after haplo-SCT; (ii) HLA-A mismatch was associated with delayed platelet engraftment; (iii) HLA-B mismatch independently correlated with significantly decreased relapse risk and improved DFS and OS; (iv) HLA-C mismatch appeared to be protective for TRM; (v) The presence of HLA-DRB1 mismatch was associated with increased incidence of grade II-IV acute GVHD.
A great number of reports suggested a deleteriously synergistic effect of HLA multiple mismatches on transplant outcomes after unrelated SCT [1] [2] [3] [4] [24] [25] [26] . Recent updated reports both by ours and others showed, however, greater HLA loci disparity had no detrimental association with outcomes after unmanipulated haplo-SCT with ATG or with PT/Cy [5, 11, 18, [27] [28] [29] [30] . Our previous study demonstrated that greater HLA antigen disparity at HLA-A, HLA-B, and HLA-DR appeared no worse overall outcome for patients who received related haplo-SCT [31, 32] . In this study, we further demonstrated that increasing HLA allele mismatches at HLA-A, HLA-B, HLA-C, HLA-DRB1, and HLA-DQB1 was not associated with worse hematopoietic recovery, higher risks of GVHD, or mortality. These results suggested that the negative impact of HLA mismatch was, at least in part, overcome by ATG or PT/Cy in haplo-SCT [30] .
Our earlier study demonstrated that HLA-B antigen mismatch was the independent risk factor for acute GVHD [18] . In current study, we did not indicate such significant association between HLA-B allele mismatch and GVHD. Several possible reasons may explained this phenomenon. First, improvements in GVHD prophylaxis and supportive care, especially the risk stratification-directed, low-dose corticosteroid prophylaxis for GVHD, had significantly decreased the cumulative incidence of grade II-IV acute GVHD, particularly in high risk group. In our previous study, the cumulative incidence of grade II-IV acute GVHD was 50.6% in HLA-B mismatch group and 31.6% in HLA-B match group. While in our current study, the cumulative incidence of grade II-IV acute GVHD decreased to 32.03% in HLA-B mismatch group and 27.59% in HLA-B match group. Second, a number of studies showed that the cumulative incidence of GVHD was gradually decreased in our transplant center [7, 12] . Patients from 2002 to 2009 were included in our previous study, while patients from 2010 to 2014 were analyzed in our present study.
The role of each HLA allele has not been established for HLA in haplo-SCT, and it still remains unclear which HLA locus mismatch is permissible. In our study, we first found that HLA-A allele mismatch was associated with delayed platelet engraftment. Since Takanashi et al. found that patients' pretransplantation anti-HLA antibodies specifically against the cord blood HLA were associated with lower platelet recovery [33] , we speculated that the anti-HLA antibody specifically against the donor HLA positivity rate was higher in the HLA-A mismatch group compared with the other loci.
The Japan Marrow Donor Program (JMDP) found that a single mismatch at HLA-A, -B, or -C was associated with higher mortality in a large study of 7898 patients [2] . In contrast with JMDP's report, we observed that HLA-B allele mismatch was associated with increased DFS and OS, and this may be involved in the lower rate of relapse in HLA-B mismatch group. Because of the different transplant protocol, the JMDP found that HLA-C mismatch reduced leukemia relapse and several amino acid substitutions on the specific positions responsible for a decreased risk of relapse were identified after unrelated bone marrow transplantation [2, 34] . Therefore, it was conceived that specific amino acid substitutions in HLA-B should be responsible for lower relapse rate after haplo-SCT. Though no studies found any single mismatch correlated with improved survival after unrelated bone marrow transplantation, Kasamon et al. reported that DRB1 antigen mismatch was associated with an improved DFS after haplo-SCT [13] . Because of the some donor origin, Kasamon et al. and our reports both found no single mismatch was associated with poor survival. Meanwhile, because of the different strategy of GVHD prophylaxis, there was contrary about which locus mismatch correlated with improved survival.
Experiences from umbilical-cord blood transplantation have shown that mismatch at HLA-C had higher TRM (HR 3.97, P = 0.018) compared to fully matched transplants [15] . In contrast, we found that HLA-C allele mismatch could be a positive factor for TRM after haplo-SCT. The result was partly consistent with the National Marrow Donor Program (NMDP) study that single mismatch at HLA-C appeared better tolerated than mismatches at HLA-A or HLA-DRB1 [1] . Because HLA-C was the ligand of the killer cell immunoglobulin-like receptor (KIR), the different effect between HLA-C and HLA-A or HLA-DRB1 might be attributable to the interaction between KIR and KIR ligand [35] .
The effect of HLA-DR on acute GVHD had been reported previously after unrelated bone marrow transplantation. Petersdorf et al. and Morishima et al. respectively demonstrated that HLA-DRB1 allele mismatch was associated with higher incidence of GVHD [3, 25] . In our study, we found that the presence of HLA-DRB1 allele mismatch was associated with increased incidence of grade II-IV acute GVHD for the whole population. However, when we considered the effect of ATG dose and low-dose corticosteroid prophylaxis, HLA-DRB1 mismatch no longer showed any effect on acute GVHD. This finding further demonstrated that improvements in GVHD prophylaxis and supportive care had greatly decreased the incidence of acute GVHD.
The JMDP and NMDP all concluded that single mismatch at HLA-DQB1 was not associated with adverse outcomes [1, 2] . In consistent with these studies, mismatching at HLA-DQB1 did not have a significant impact on transplant outcomes. These results might be due to the poor immunogenicity of common HLA-DQB1 allelic products. Therefore, compared with other loci, HLA-DQB1 had the least importance in haplo-SCT.
Our study was limited by the characteristics inherent to single center, retrospective analyses. Additionally, in spite this was the largest study evaluating effect of HLA allele mismatch on clinical outcome in halpo-SCT, only a small cohort of patients were analyzed in this study. Therefore, larger data from prospective multicenter study was needed for the further validation of these results.
In conclusion, we performed HLA allele typing for HLA-A, -B, -C, -DRB1, and -DQB1, and updated the experience of HLA disparity on clinical outcomes after haplo-SCT. We suggest that greater HLA allele mismatches in haplo-SCT was not associated with poor transplant outcomes. HLA-B mismatch showed a protection against relapse and was associated with approving transplant outcome.
